EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials

Adele Gaspar Lopes iD, Sampath Kumar Loganathan, Jayalakshmi Caliaperumal iD

Brain Sciences · 24.01.2024 · 14 (2) · 120

DOI: 10.3390/brainsci14020120 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 24.01.2024. Verfasst von Adele Gaspar Lopes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett syndrome (RTT) is a neurological disorder that mostly affects females, with a frequency of 1 in 10,000 to 20,000 live birth cases. Symptoms include stereotyped hand movements; impaired learning, language, and communication skills; sudden loss of speech; reduced lifespan; retarded growth; disturbance of sleep and breathing; seizures; autism; and gait apraxia. Pneumonia is the most common cause of death for patients with Rett syndrome, with a survival rate of 77.8% at 25 years of age. Survival into the fifth decade is typical in Rett syndrome, and the leading cause of death is cardiorespiratory compromise. Rett syndrome progression has multiple stages; however, most phenotypes are associated with the nervous system and brain. In total, 95% of Rett syndrome cases are due to mutations in the MECP2 gene, an X-linked gene that encodes for the methyl CpG binding protein, a regulator of gene expression. In this review, we summarize the recent developments in the field of Rett syndrome and therapeutics targeting MECP2.

Schlagwörter

Stichwörter der Autor:innen

MECP2Rett syndromeneurodevelopmental disorderstrofinetide

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.
  • Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
  • Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
  • Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
  • Departments of Experimental Surgery and Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
  • Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2M7, Canada.

ORCID-Profile: Adele Gaspar Lopes, Jayalakshmi Caliaperumal

Zitieren

APA

Lopes, A. G., Loganathan, S. K., & Caliaperumal, J. (2024). Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials. Brain Sciences, 14(2), 120. https://doi.org/10.3390/brainsci14020120

Vancouver

Lopes AG, Loganathan SK, Caliaperumal J. Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials. Brain Sciences. 2024;14(2):120. doi:10.3390/brainsci14020120

BibTeX
@article{Lopes2024,
  author = {Lopes, Adele Gaspar and Loganathan, Sampath Kumar and Caliaperumal, Jayalakshmi},
  title = {Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials},
  journal = {Brain Sciences},
  year = {2024},
  volume = {14},
  number = {2},
  pages = {120},
  doi = {10.3390/brainsci14020120}
}
Kostenlos starten →